Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dantrolene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.98 |
| ▸ | MEN1 | O00255 | 7/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.98 |
| ▸ | LMNA | P02545 | 5/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.98 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | MAOA | P21397 | 1/20 | 0.66 |
| ▸ | CASP7 | P55210 | 1/20 | 0.66 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dantrolene SCHEMBL4223149 | 1.00 | MAPT (0.98) | MAPTMEN1KMT2ALMNATDP1 | |
| Dantrolene SCHEMBL1074048 | 0.99 | MAPT (0.96) | MAPTMEN1KMT2ALMNATDP1 | |
| Dantrolene SCHEMBL56848 | 0.99 | MAPT (1.00) | MAPTMEN1KMT2ALMNATDP1 | |
| Dantrolene SCHEMBL40893 | 0.99 | MAPT (1.00) | MAPTMEN1KMT2ALMNATDP1 | |
| Dantrolene SCHEMBL946529 | 0.98 | MAPT (0.98) | MAPTMEN1KMT2ALMNATDP1 | |
| Dantrolene SCHEMBL29510578 | 0.98 | MAPT (0.98) | MAPTMEN1KMT2ALMNATDP1 | |
| Dantrolene SCHEMBL2903719 | 0.98 | MAPT (0.98) | MAPTMEN1KMT2ALMNATDP1 | |
| Dantrolene SCHEMBL979318 | 0.98 | MAPT (0.98) | MAPTMEN1KMT2ALMNATDP1 | |
| Dantrolene SCHEMBL1074050 | 0.97 | MAPT (0.96) | MAPTMEN1KMT2ALMNATDP1 | |
| Dantrolene SCHEMBL1074051 | 0.97 | MAPT (0.96) | MAPTMEN1KMT2ALMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115582040-A | Preparation device and preparation method of dantrolene sodium raw material | 江西希尔康泰制药有限公司 | 2023-01-10 | — | — | CN | disclosed |
| CN-115400454-A | Dantrolene sodium extraction device and use method thereof | 江西希尔康泰制药有限公司 | 2022-11-29 | — | — | CN | disclosed |
| US-20220087980-A1 | METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE | EAGLE PHARMACEUTICALS, INC. | 2022-03-24 | — | — | US | disclosed |
| US-11123328-B2 | Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction | UNIVERSITY HEALTH NETWORK (CA) | 2021-09-21 | — | — | US | disclosed |
| EP-2994134-B1 | METHODS OF ADMINISTERING DANTROLENE FOR THE ACUTE TREATMENT OF CARDIAC ARRHYTHMIAS | UNIV HEALTH NETWORK (CA) | 2021-06-23 | — | — | EP | disclosed |
| US-20200383954-A1 | METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE | EAGLE PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200375951-A1 | DANTROLENE AND ANALOGS THEREOF FOR THE CHRONIC TREATMENT AND PREVENTION OF DYSSYNCHRONOUS CARDIAC DYSFUNCTION | UNIVERSITY HEALTH NETWORK (CA) | 2020-12-03 | — | — | US | disclosed |
| CN-111825662-A | Dantrolene sodium crystal form and preparation method thereof | 丽珠医药集团股份有限公司 | 2020-10-27 | — | — | CN | disclosed |
| CN-111093652-A | Methods of treating nerve agent exposure using dantrolene | 伊格尔制药公司 | 2020-05-01 | — | — | CN | disclosed |
| US-9636327-B2 | Methods of administering dantrolene for the acute treatment of cardiac arrhythmias | UNIVERSITY HEALTH NETWORK (CA) | 2017-05-02 | — | — | US | disclosed |
| US-20160101085-A1 | METHODS OF ADMINISTERING DANTROLENE FOR THE ACUTE TREATMENT OF CARDIAC ARRHYTHMIAS | University Health Network, Toronto General Hospita (CA) | 2016-04-14 | — | — | US | disclosed |
| US-8975284-B2 | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents | US WORLDMEDS LLC (US) | 2015-03-10 | — | — | US | disclosed |
| EP-2583670-A1 | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents | US Worldmeds LLC (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2219605-A1 | CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS | US Worldmeds LLC (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009048698-A9 | CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS | US WORLDMEDS LLC (US) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009048698-A1 | CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS | US WORLDMEDS LLC (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20090093531-A1 | Co-Solvent Compositions and Methods for Improved Delivery of Dantrolene Therapeutic Agents | US WORLDMEDS LLC | 2009-04-09 | — | — | US | disclosed |
| US-4861790-A | Use of azumolene for the treatment of malignant hyperthermia | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1989-08-29 | — | — | US | disclosed |
| US-4543359-A | Treating cardiac arrhythmias with dantrolene sodium | EATON LABORATORIES, INC. (US) | 1985-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093531-A1 | Co-Solvent Compositions and Methods for Improved Delivery of Dantrolene Therapeutic Agents | TERT, TBCA, TTR | MAPT 677/4885MEN1 2329/4885KMT2A 1079/4885 |
| US-20200375951-A1 | DANTROLENE AND ANALOGS THEREOF FOR THE CHRONIC TREATMENT AND PREVENTION OF DYSSYNCHRONOUS CARDIAC DYSFUNCTION | RYR2, TNNC1, TNNT2 | MAPT 4617/4885MEN1 3456/4885KMT2A 2427/4885 |
| US-20220087980-A1 | METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE | PMP22, CNTN1, SMN1; SMN2 | MAPT 1073/4885MEN1 1585/4885KMT2A 2950/4885 |
| US-11123328-B2 | Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction | RYR2, TNNC1, TNNT2 | MAPT 4701/4885MEN1 3761/4885KMT2A 2898/4885 |
| US-20200383954-A1 | METHODS OF USING DANTROLENE TO TREAT NERVE AGENT EXPOSURE | PMP22, CNTN1, SMN1; SMN2 | MAPT 1073/4885MEN1 1585/4885KMT2A 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.